Dublin, April 18, 2019 (GLOBE NEWSWIRE) -- The "Global Genital Herpes Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global genital herpes treatment drugs market is expected to expand at a CAGR of 4.9% from 2018 to 2026.
There is a changing trend in the treatment of genital herpes infection, wherein biologist is primarily focusing on developing vaccines to bolster immunity in ailing patients and address the problem of lesion recurrence.
Acyclovir is presently dominating the drug class for the genital herpes treatment drugs market. The primary features responsible for the dominance of acyclovir are its excellent therapeutic efficacy, dose tolerance with negligible toxicity. It is currently the drug of the first choice for the treatment of genital herpes with a prescribed dose of 200 mg five times daily for 10 days.
Famciclovir has gained prominence on account of its higher oral bioavailability which is employed for the treatment of genital herpes patients suffering from lesion recurrence.
North America is currently reigning the geographical segment for genital herpes treatment drugs market. According to the Center for Disease Control and Prevention (CDC), genital herpes is occurring 1in every 6 citizens in the United States. The rising prevalence of sexually transmitted disease and effective treatment guidelines drive the genital herpes treatment drugs market growth in North America.
Affordable reimbursement scenario and domicile of major players such as AstraZeneca, GlaxoSmithKline and Novartis propel the genital herpes treatment drugs market growth in the European region.
Asia Pacific will register rapid growth during the forecast period from 2018 to 2026 owing to the rising prevalence of HSV-1 infected patients, increasing public health awareness and presence of huge generic drugs for the treatment of genital herpes infection.
Key Market Movements
- The rising prevalence of sexually transmitted disease worldwide
- Increasing public health awareness and affordable reimbursement scenario drive the genital herpes treatment drugs market
- Excellent product pipeline catering therapeutics vaccines to bolster patient immunity such as GEN-003 and VCL-HB01
Topics Covered
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Genital Herpes Treatment Drugs Market Portraiture
2.2. Global Genital Herpes Treatment Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Genital Herpes Treatment Drugs Market, by Geography, 2017 (US$ Mn)
Chapter 3. Genital Herpes Treatment Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Genital Herpes Treatment Drugs Market, by Key Players, 2017
Chapter 4. Global Genital Herpes Treatment Drugs Market, by Drug Class
4.1. Overview
4.2. Acyclovir
4.3. Famciclovir
4.4. Valacyclovir
4.5. Pipeline Analysis
Chapter 5. Global Genital Herpes Treatment Drugs Market, by Geography
5.1. Overview
5.2. North America Genital Herpes Treatment Drugs Market Analysis, 2016-2026
5.3. Europe Genital Herpes Treatment Drugs Market Analysis, 2016-2026
5.4. Asia Pacific Genital Herpes Treatment Drugs Market Analysis, 2016-2026
5.5. Latin America Genital Herpes Treatment Drugs Market Analysis, 2016-2026
5.6. Middle East and Africa Genital Herpes Treatment Drugs Market Analysis, 2016-2026
Chapter 6. Company Profiles
6.1. AstraZeneca PLC
6.2. Apotheca Inc.
6.3. Asahi Kasei Pharma Corporation
6.4. Carlsbad Technology Inc.
6.5. GlaxoSmithKline PLC
6.6. Mylan N.V.
6.7. Novartis AG
6.8. Merck & Co. Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Zydus Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/1z1kcp